OT4B is a brand that was established in 2017 with the aim of developing and making accessible the use of Oxytocin as the primary treatment for patients with Prader-Willi syndrome. This brand is dedicated to improving the lives of patients and their families. Partnering with the University Hospital of Toulouse, OT4B focuses on conducting research on Oxytocin and Prader-Willi syndrome from early infancy through adulthood.

Their approach involves providing early treatment to newborns with Prader-Willi syndrome, as it is believed that this could have a significant impact on their development trajectory. Oxytocin, a hormone produced naturally in the brain, acts as a neuromodulator and has been linked to the syndrome. Through their commitment to research and patient-centric approach, OT4B aims to bring hope and better outcomes to individuals with Prader-Willi syndrome and their loved ones